Enalapril versus losartan for adults with chronic kidney disease: A systematic review and meta-analysis

Nephrology

Volumn 18, Issue 9, 2013, Pages 605-614

  He, Yuan Mei ^a   Feng, Li ^a   Huo, Dong Mei ^a   Yang, Zhen Hua ^a   Liao, Yun Hua ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

adults; chronic kidney disease; enalapril; losartan

Indexed keywords

ENALAPRIL; LOSARTAN; URIC ACID;

ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; COUGHING; HUMAN; HYPERTENSION; KIDNEY FUNCTION; META ANALYSIS; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT DURATION; URIC ACID BLOOD LEVEL; URINALYSIS;

ADULTS; CHRONIC KIDNEY DISEASE; ENALAPRIL; LOSARTAN;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CHI-SQUARE DISTRIBUTION; COUGH; CREATININE; ENALAPRIL; FEMALE; HUMANS; KIDNEY; LOSARTAN; MALE; MIDDLE AGED; ODDS RATIO; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; TREATMENT OUTCOME; URIC ACID;

EID: 84883286618     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12134     Document Type: Article

References (43)

1. Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: Approaches and initiatives-a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007; 72: 247-259.
2. Taal MW, Brenner BM,. Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists. Kidney Int. 2000; 57: 1803-1817.
3. Blantz RC, Gabbai FB,. Effect of angiotensin II on glomerular hemodynamics and ultrafiltration coefficient. Kidney Int. Suppl. 1987; 20: S108-111.
4. Blankestijn PJ, Ligtenberg G,. Volume-independent mechanisms of hypertension in hemodialysis patients: Clinical implications. Semin. Dial. 2004; 17: 265-269.
5. Yerkey MW, Kernis SJ, Franklin BA, Sandberg KR, McCullough PA,. Renal dysfunction and acceleration of coronary disease. Heart 2004; 90: 961-966.
6. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
7. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001; 345: 861-869.
8. Remuzzi A, Gagliardini E, Sangalli F, et al. ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. Kidney Int. 2006; 69: 1124-1130.
9. Weil EJ, Fufaa G, Jones LI, et al. Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes. Diabetes 2013; [Epub ahead of print]
10. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 2007; 25: 1105-1187.
11. Matsuda H, Hayashi K, Arakawa K, et al. Zonal heterogeneity in action of angiotensin-converting enzyme inhibitor on renal microcirculation: Role of intrarenal bradykinin. J. Am. Soc. Nephrol. 1999; 10: 2272-2282.
12. Kon V, Fogo A, Ichikawa I,. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int. 1993; 44: 545-550.
13. Siragy HM, Jaffa AA, Margolius HS, Carey RM,. Renin-angiotensin system modulates renal bradykinin production. Am. J. Physiol. 1996; 271: R1090-1095.
14. Sharma P, Blackburn RC, Parke CL, McCullough K, Marks A, Black C,. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease. Cochrane Database Syst. Rev. 2011; (10) CD007751.
15. Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC,. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst. Rev. 2006; (4) CD006257.
16. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am. J. Kidney Dis. 2002; 39: S1-266.
17. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control. Clin. Trials 1986; 7: 177-188.
18. Higgins JPT, Green S, (eds) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. [updated March 2011]. Cambridge: The Cochrane Collaboration, Available from URL: www.cochrane-handbook.org.2011
19. Higgins JP, Thompson SG,. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002; 21: 1539-1558.
20. Schulz KF, Chalmers I, Hayes RJ, Altman DG,. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-412.
21. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH,. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int. 2000; 57: 601-606.
22. Cetinkaya R, Odabas AR, Selcuk Y,. Anti-proteinuric effects of combination therapy with enalapril and losartan in patients with nephropathy due to type 2 diabetes. Int. J. Clin. Pract. 2004; 58: 432-435.
23. Hoque R, Rahman MS, Iqbal M,. Effect of enalapril and losartan on proteinuria in type 2 diabetic nephropathy patients. Bangladesh Med. Res. Counc. Bull. 2009; 35: 44-48.
24. Klein IHHT, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ,. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J. Am. Soc. Nephrol. 2003; 14: 425-430.
25. Lacourcière Y, Bélanger A, Godin C, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int. 2000; 58: 762-769.
26. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N. Engl. J. Med. 2009; 36: 40-51.
27. Renke M, Tylicki L, Rutkowski P, Rutkowski B,. Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis. Scand. J. Urol. Nephrol. 2004; 38: 427-433.
28. Reyes-Marín FA, Calzada C, Ballesteros A, Amato D,. Comparative study of enalapril vs. losartan on residual renal function preservation in automated peritoneal dialysis. A randomized controlled study. Rev. Invest. Clin. 2012; 64: 315-321.
29. Russo D, Minutolo R, Pisani A, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am. J. Kidney Dis. 2001; 38: 18-25.
30. Shand BI,. Haemorheological effects of losartan and enalapril in patients with renal parenchymal disease and hypertension. J. Hum. Hypertens. 2000; 14: 305-309.
31. Shibasaki Y, Nishiue T, Masaki H, Matsubara H, Iwasaka T,. Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD). Nippon Rinsho 2002; 60: 1992-1998.
32. Shibasaki Y, Nishiue T, Masaki H, et al. Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: Assessment by ultrasonic integrated backscatter and biochemical markers. Hypertens. Res. 2005; 28: 787-795.
33. Suzuki H, Kanno Y, Kaneko K, et al. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy. Ther. Apher. Dial. 2004; 8: 320-327.
34. Tan F, Mukherjee JJ, Lee KO, Lim P, Liew CF,. Dual blockade of the renin-angiotensin-aldosterone system is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy. Singapore Med. J. 2010; 51: 151-156.
35. Tylicki L, Renke M, Rutkowski P, Rutkowski B, Lysiak-Szyd?owska W,. Randomized, controlled study of the effects of losartan versus enalapril in small doses on proteinuria and tubular injury in primary glomerulonephritis. Med. Sci. Monit. 2005; 11: Pi31-37.
36. Tylicki L, Rutkowski P, Renke M, Rutkowski B,. Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis: Short-term observation. Am. J. Nephrol. 2002; 22: 356-362.
37. Woo KT, Chan CM, Tan HK, et al. Beneficial effects of high-dose losartan in IgA nephritis. Clin. Nephrol. 2009; 71: 617-624.
38. Lafayette RA, Mayer G, Park SK, Meyer TW,. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J. Clin. Invest. 1992; 90: 766-771.
39. Nielsen S, Dollerup J, Nielsen B, Jensen HA, Mogensen CE,. Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. Nephrol. Dial. Transplant. 1997; 12 (Suppl 2): 19-23.
40. Kakinuma Y, Kawamura T, Bills T, Yoshioka T, Ichikawa I, Fogo A,. Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int. 1992; 42: 46-55.
41. Li YF, Zhu XM, Liu F, et al. Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism and ACE inhibitor-related cough: A meta-analysis. PLoS ONE 2012; 7: e37396.
42. Jaspard E, Wei L, Alhenc-Gelas F,. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J. Biol. Chem. 1993; 268: 9496-9503.
43. Smeeth L, Haines A, Ebrahim S,. Numbers needed to treat derived from meta-analyses-sometimes informative, usually misleading. BMJ 1999; 318: 1548-1551.